» Articles » PMID: 27072810

Identification of HLA-A*11:01-restricted Mycobacterium Tuberculosis CD8(+) T Cell Epitopes

Overview
Journal J Cell Mol Med
Date 2016 Apr 14
PMID 27072810
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

New vaccines are needed to combat Mycobacterium tuberculosis (MTB) infections. The currently employed Bacillus Calmette-Guérin vaccine is becoming ineffective, due in part to the emergence of multidrug-resistant tuberculosis (MDR-TB) strains and the reduced immune capacity in cases of HIV coinfection. CD8(+) T cells play an important role in the protective immunity against MTB infections, and the identification of immunogenic CD8(+) T cell epitopes specific for MTB is essential for the design of peptide-based vaccines. To identify CD8(+) T cell epitopes of MTB proteins, we screened a set of 94 MTB antigens for HLA class I A*11:01-binding motifs. HLA-A*11:01 is one of the most prevalent HLA molecules in Southeast Asians, and definition of T cell epitopes it can restrict would provide significant coverage for the Asian population. Peptides that bound with high affinity to purified HLA molecules were subsequently evaluated in functional assays to detect interferon-γ release and CD8(+) T cell proliferation in active pulmonary TB patients. We identified six novel epitopes, each derived from a unique MTB antigen, which were recognized by CD8(+) T cells from active pulmonary TB patients. In addition, a significant level of epitope-specific T cells could be detected ex vivo in peripheral blood mononuclear cells from active TB patients by an HLA-A*11:01 dextramer carrying the peptide Rv3130c194-204 (from the MTB triacylglycerol synthase Tgs1), which was the most frequently recognized epitope in our peptide library. In conclusion, this study identified six dominant CD8(+) T cell epitopes that may be considered potential targets for subunit vaccines or diagnostic strategies against TB.

Citing Articles

Evaluation of the consistence between the results of immunoinformatics predictions and real-world animal experiments of a new tuberculosis vaccine MP3RT.

Cheng P, Xue Y, Wang J, Jia Z, Wang L, Gong W Front Cell Infect Microbiol. 2022; 12:1047306.

PMID: 36405961 PMC: 9666678. DOI: 10.3389/fcimb.2022.1047306.


Designing multi-epitope based peptide vaccine candidates against SARS-CoV-2 using immunoinformatics approach.

Ysrafil Y, Sapiun Z, Astuti I, Anasiru M, Slamet N, Hartati H Bioimpacts. 2022; 12(4):359-370.

PMID: 35975206 PMC: 9376164. DOI: 10.34172/bi.2022.23769.


Antigen presentation by MHC-E: a putative target for vaccination?.

Voogd L, Ruibal P, Ottenhoff T, Joosten S Trends Immunol. 2022; 43(5):355-365.

PMID: 35370095 PMC: 9058203. DOI: 10.1016/j.it.2022.03.002.


Association between HLA alleles and sub-phenotype of childhood steroid-sensitive nephrotic syndrome.

Lee H, Wang L, Ni F, Yang X, Feng S, Gao X World J Pediatr. 2022; 18(2):109-119.

PMID: 34973118 PMC: 8843916. DOI: 10.1007/s12519-021-00489-y.


Identification of HLA-A2 restricted epitopes of glypican-3 and induction of CTL responses in HLA-A2 transgenic mice.

Jin X, Liu X, Zhou Z, Ding Y, Wu Y, Qiu J Cancer Immunol Immunother. 2021; 71(7):1569-1582.

PMID: 34724090 PMC: 10992247. DOI: 10.1007/s00262-021-03096-y.


References
1.
Commandeur S, Lin M, van Meijgaarden K, Friggen A, Franken K, Drijfhout J . Double- and monofunctional CD4⁺ and CD8⁺ T-cell responses to Mycobacterium tuberculosis DosR antigens and peptides in long-term latently infected individuals. Eur J Immunol. 2011; 41(10):2925-36. DOI: 10.1002/eji.201141602. View

2.
Scholler J, Singh M, Bergmeier L, Brunstedt K, Wang Y, Whittall T . A recombinant human HLA-class I antigen linked to dextran elicits innate and adaptive immune responses. J Immunol Methods. 2010; 360(1-2):1-9. DOI: 10.1016/j.jim.2010.05.008. View

3.
Hoppes R, Ekkebus R, Schumacher T, Ovaa H . Technologies for MHC class I immunoproteomics. J Proteomics. 2010; 73(10):1945-53. DOI: 10.1016/j.jprot.2010.05.009. View

4.
Kaufmann S . How can immunology contribute to the control of tuberculosis?. Nat Rev Immunol. 2002; 1(1):20-30. DOI: 10.1038/35095558. View

5.
Raviglione M, Marais B, Floyd K, Lonnroth K, Getahun H, Migliori G . Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet. 2012; 379(9829):1902-13. DOI: 10.1016/S0140-6736(12)60727-2. View